+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer



A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer



Vaccine 31(6): 943-949



PSMA-VRP is a propagation defective, viral replicon vector system encoding PSMA under phase I evaluation for patients with castration resistant metastatic prostate cancer (CRPC). The product is derived from an attenuated strain of the alphavirus, Venezuelan Equine Encephalitis (VEE) virus, and incorporates multiple redundant safety features. In this first in human trial, two cohorts of 3 patients with CRPC metastatic to bone were treated with up to five doses of either 0.9×10(7)IU or 0.36×10(8)IU of PSMA-VRP at weeks 1, 4, 7, 10 and 18, followed by an expansion cohort of 6 patients treated with 0.36×10(8)IU of PSMA-VRP at weeks 1, 4, 7, 10 and 18. No toxicities were observed. In the first dose cohort, no PSMA specific cellular immune responses were seen but weak PSMA-specific signals were observed by ELISA. The remaining 9 patients, which included the higher cohort and the extension cohort, had no PSMA specific cellular responses. PSMA-VRP was well-tolerated at both doses. While there did not appear to be clinical benefit nor robust immune signals at the two doses studied, neutralizing antibodies were produced by both cohorts suggesting that dosing was suboptimal.

(PDF emailed within 0-6 h: $19.90)

Accession: 051207938

Download citation: RISBibTeXText

PMID: 23246260

DOI: 10.1016/j.vaccine.2012.11.096


Related references

Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology 23(16_suppl): 4615-4615, 2016

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet. Oncology 13(5): 501-508, 2012

Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. Journal of Nuclear Medicine 59(4): 625-631, 2017

Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). Journal of Clinical Oncology 24(18_suppl): 4500-4500, 2016

A phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy. Cancer Gene Therapy 10(Supplement 1): S13-S14, January, 2003

Phase 2 trial of 177 Lutetium ( 177 Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 ( 177 Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology 24(18_suppl): 4613-4613, 2016

Assessing the immune status of prostate cancer patients infused with dendritic cells expressing prostate-specific membrane antigen peptides during a phase II clinical trial. FASEB Journal 13(4 PART 1): A303, March 12, 1999

Assessing the immune status of prostate cancer patients infused with dendritic cells expressing prostate-specific membrane antigen peptides during a phase II clinical trial. FASEB Journal 13(4 PART 1): A303, March 12, 1999

Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). Journal of Clinical Oncology 26(15_suppl): 5140-5140, 2016

Monitoring of prostate-specific membrane antigen- specific immune responses and prostate markers in a phase II clinical trial with patients infused with dendritic cells pulsed with PSMA-derived peptides. Proceedings of the American Association for Cancer Research Annual Meeting 39: 173, March, 1998

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38(1): 73-78, Jan 1, 1999

Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. Prostate 2019, 2019

Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 42(13): 1976-1983, 2016

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic Oncology 34(12): 530.E15-530.E21, 2016

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. Bju International 120(2): 197-203, 2016